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Abstract
Background: Axillary node status after induction chemotherapy for locally advanced breast cancer has
been shown on multivariate analysis to be an independent predictor of relapse. However, it has been
postulated that responders to induction chemotherapy with a clinically negative axilla could be spared
the burden of lymphadenectomy, because most of them will not show histological nodal invasion. P-
glycoprotein expression in the rescue mastectomy specimen has finally been identified as a significant
predictor of patient survival.
Materials and methods: We studied the expression of the genes encoding multidrug resistance
associated protein (MDR1) and lung cancer associated resistance protein (LRP) in formalin-fixed,
paraffin-embedded tumor samples from 52 patients treated for locally advanced breast cancer by
means of induction chemotherapy followed by rescue mastectomy. P-glycoprotein expression was
assessed by means of immunohistochemistry before treatment in 23 cases, and by means of reverse-
transcriptase-mediated polymerase chain reaction (RT–PCR) after treatment in 46 (6 failed). LRP
expression was detected by means of immunohistochemistry, with the LRP-56 monoclonal antibody, in
31 cases before treatment. Immunohistochemistry for detecting the expression of c-erb-B2, p53, Ki67,
estrogen receptor and progesterone receptor are routinely performed in our laboratory in every case,
and the results obtained were included in the study. All patients had received between two and six
cycles of standard 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy, with two
exceptions [one patient received four cycles of a docetaxel–adriamycin combination, and the other four
cycles of standard cyclophosphamide–methotrexate–5-fluorouracil (CMF) polychemotherapy].
Response was assessed in accordance with the Response Evaluation Criteria In Solid Tumors
(RECIST). By these, 2 patients achieved a complete clinical response, 37 a partial response, and the
remaining 13 showed stable disease. This makes a total clinical response rate of 75.0%. None
achieved a complete pathological response.
Results: MDR1 mRNA expression detected by RT–PCR was associated with the presence of invaded
axillary nodes at surgery in 18/22 cases (81.8%), compared with 13/24 (54.2%) in the group with
undetectable MDR1 expression. This difference was statistically significant (P < 0.05). LRP expression
in more than 20% of tumor cells before any treatment was associated with axillary nodal metastasis
after chemotherapy and rescue mastectomy in 17/23 cases, compared with 3/8 in nonexpressors.
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Introduction
Induction chemotherapy (or induction hormone therapy),
followed by rescue mastectomy, with or without axillary
dissection, is the most widely accepted standard of treat-
ment for primarily inoperable breast cancer [1]. During the
past two or three decades, this approach has been also
employed increasingly for the downstaging of ‘locally
advanced breast cancer’, a poorly defined term encom-
passing both primarily inoperable cancers and those that
are strictly operable but present unfavorable prognostic
features (such as large size, diffuse tumors and clinically
involved axillary nodes). Consensus pending, it might be
acceptable to include in this category any tumor from
stage IIA and above from the International Federation of
Gynecology and Obstetrics (FIGO) classification, with the
still unresolved issue of whether inflammatory carcinomas
belong to this group or are a completely different class of
tumor [2]. The last step in this direction has been to
submit patients with otherwise operable cancers to
neoadjuvant chemotherapy, to increase the proportion of
those amenable to breast conservation [3].
Axillary node status after induction chemotherapy for
locally advanced breast cancer has been shown on mul-
tivariate analysis to be an independent predictor of
relapse [4]. Complete pathological tumor response to
induction chemotherapy has been shown to predict a
tumor-free axilla on histology in 4 out of 22 instances
(more than 90%) [5]. As an extension of this, it has been
postulated that responders to induction chemotherapy
with a clinically negative axilla could be spared the
burden of lymphadenectomy, because most of them will
not show histological nodal invasion [3]. It would be
interesting to identify mechanisms involved in the resis-
tance to induction chemotherapy, because, arguably, it is
from resistant clones that the shedding of tumor cells
giving rise to local and distant metastasis can take place.
An argument in favor of this hypothesis is the fact that P-
glycoprotein expression in the rescue mastectomy speci-
men has been identified as a significant predictor of
patient survival [6]. Because cancer-related death in
breast cancer patients is ultimately caused by distant
metastasis in most cases, it seems [6] that P-glycopro-
tein expression could indicate the presence of multidrug-
resistant clones, from which tumor recurrence and
dissemination might arise.
However, expression of the gene encoding multidrug
resistance associated protein (MDR1) is not the sole
factor responsible for multidrug resistance, either in breast
cancer or in any other tumor. If anything is clear at present
about multidrug resistance, it is the fact that its possible
causes are manifold and increasing with every new resis-
tance-associated gene studied [7]. Therefore, the difficulty
instead lies in which of the genes to investigate, and for
which reasons, because the potential candidates are
many. We have centered the present investigation on
P-glycoprotein and lung cancer associated resistance
protein (LRP) because adriamycin (doxorubicin) is the
main chemotherapeutic agent in most combinations used
when treating breast cancer patients with neoadjuvant
therapy. P-glycoprotein (MDR1)-associated resistance is
the paradigm of adriamycin-mediated resistance, at least
under experimental conditions. In contrast, LRP is known
to have a role in the chemoresistance of several cancers,
most notably lung cancer (from which it derives its name),
but also leukemias and ovarian cancer [8–10]. However, it
has not been studied extensively until now in breast
cancer, although Volm et al [11] have clearly shown that
LRP is involved in resistance to adriamycin, and would
therefore be a good candidate for research in association
with this tumor for the above-mentioned reasons.
Again, this difference was highly significant (P < 0.01). LRP expression before treatment and MDR1
mRNA expression after treatment were significantly interrelated (P < 0.001), which might reflect the
presence of chemoresistant clones liable to metastasize to the regional nodes. Persistence of
previously detected MDR1-positivity after treatment (7/9 compared with 0/2 cases) was significantly
associated with axillary node metastasis (P < 0.05). Finally, in a logistic regression multivariate model,
histology other than ductal, a Ki67 labeling index of at least 20% and the combination of LRP and
MDR1 positivity emerged as independent predictors of axillary node invasion at the time of rescue
mastectomy.
Conclusion: The expression of different genes involved in resistance to chemotherapy, both before
and after treatment with neoadjuvant, is associated with the presence of axillary node invasion at
rescue surgery in locally advanced breast cancer. This might reflect the presence of intrinsically
resistant clones before any form of therapy, which persist after it, and could be helpful both for
prognosis and for the choice of individual treatment.
Keywords: axillary nodes, chemotherapy, LRP, multidrug resistant, neoadjuvantc
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We have studied the expression of MDR1 and LRP both
before and after neoajuvant chemotherapy in the present
series of patients. The results have been correlated with
the response to treatment, the presence of invaded axillary
nodes, and also with that of other conventional prognostic
markers (hormone receptors, Ki67 labeling index, mutant
p53 expression, and c-erb-B2 overexpression).
Materials and methods
For the present investigation we used tumor material from
52 patients operated on at our center after induction
chemotherapy for locally advanced breast cancer. This
consisted of three to six cycles of standard FAC (5-fluo-
rouracyl, doxorubicin and cyclophosphamide, 500, 50 and
500 mg/m2, respectively, given on day 1 every 21 days) in
50 cases, the remaining two receiving four cycles of doc-
etaxel–doxorubicin (70 mg/m2 and 100 mg/m2 on day 1
every 21 days) and four cycles of standard cyclophos-
phamide–methotrexate–5-fluorouracil (CMF), respectively.
Four courses of chemotherapy were initially planned for
every patient. Most of them completed this schedule
(41/52). However, one patient received only two courses
(owing to intolerance, accompanied by an excellent tumor
response) and six patients were given three courses for
similar reasons; at the other extreme, one and three
patients needed five and six cycles of chemotherapy,
respectively, to make them amenable to rescue surgery,
Response to treatment was evaluated in accordance with
the newly recommended Response Evaluation Criteria In
Solid Tumors (RECIST) [12]. By these criteria, after the
completion of treatment, two patients showed a complete
clinical response, 37 a partial response and 13 stable
disease, yielding a total response rate of 75.0%. For the
assessment of tumor size we took the combined value of
radiological and ultrasonographic measurements whenever
possible (which was not true of the four diffuse tumors of
the series, occupying clinically the whole breast). As an
example, we considered a response to be partial if the
combined value of the diminution in maximal diameter
measured by both methods exceeded 30%. This resulted
in tumor sizes that were almost always less than those
obtained by palpation, but permitted a more objective mon-
itoring of response, according to the RECIST recommen-
dations, because real tumor shrinkage is evaluated in this
way and is not confounded by the response to therapy of
the peritumoral inflammatory reaction. Initial tumor size thus
ranged between 2.0 and 10.0 cm, seven of them being
T4b tumors (with clinically evident skin ulceration or histo-
logical confirmation of dermal invasion), and one a small
(2.0 cm) T4a carcinoma, fixed to the chest wall. Finally, in
four patients two or more distinct tumor masses were iden-
tified in the mammograms. Histologically, 45 were infiltrat-
ing ductal carcinomas, six were lobular carcinomas, and
the remaining one was an anaplastic, unclassifiable carci-
noma, probably of ductal origin.
All cases were diagnosed pretherapeutically by means of
a core biopsy, at which time hormone receptors, c-erb-B2,
mutant p53 expression and the Ki67 labeling index were
routinely determined. The immunohistochemical technique
and the antibodies used are the standard ones employed
at our laboratory, identical to those described recently by
us for a series of T1 breast cancers [13]. At rescue mas-
tectomy, 35 patients showed axillary nodal invasion, the
number of affected nodes ranging between 1 and 32.
Roughly one-third of these patients (12/35) had 10 or
more metastatic nodes (Table 1).
Immunohistochemistry
For the detection of MDR1 and LRP expression, we used
the same technique as that described in [13], which
involves microwave heating of the slides in citrate buffer for
antigen unmasking [heat-induced epitope retrieval (HIER)].
The antibodies used were c494 (which reportedly does not
cross-react with MDR3 and recognizes an internal epitope
of P-glycoprotein) (10 mg/ml) and LRP-56 (0.5 mg/ml). For
the evaluation of the MDR and LRP results we employed
the semiquantitative scale used previously by us [14,15],
which takes into account both the strength of the staining
reaction and the proportion of reactive tumor cells. After
application of the scale, tumors were considered positive
for MDR1 when there was distinct membrane staining
(besides the ubiquitous and difficult to interpret cytoplas-
mic staining, which was more or less present in all speci-
mens) in more than 10% of the tumor cells, and for LRP
when more than 20% of the tumor cells showed specific
staining against a negative background.
Immunohistochemistry in the rescue mastectomy speci-
mens immediately after chemotherapy was useless, owing
to huge background staining (which was often more
intense than the one found in tumor cells) and the nonspe-
cific (but also extremely strong) staining of tumor areas
that were identified in the corresponding hematoxylin–
eosin slides as areas of post-chemotherapy necrosis.
Therefore, because a given gene can be transcribed only
by living cells, in this study we considered only the pres-
ence of mRNA as indicative of MDR1 expression by the
tumor after recent chemotherapeutic treatment. The anti-
bodies used and positivity cutoffs (more than 10% posi-
tive tumor cells) for c-erb-B2, p53, estrogen receptor and
progesterone receptor were the same as those described
in [13] and routinely employed at our laboratory.
Reverse-transcriptase-mediated polymerase chain
reaction (RT–PCR)
Three or four 10 mm paraffin sections, corresponding to
about 10 mg of tissue, were trimmed of excess paraffin
and placed in 1.5 ml Eppendorf tubes with 1 ml of xylene,
vortex-mixed and centrifuged for 5 min at room tempera-
ture. The pellet was resuspended in 200 ml of PCR buffer
(200 mM Tris–HCl, pH 8.4, 500 mM KCl, 20 mM MgCl2,
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Table 1
Clinical features of tumors, immunohistochemistry of tru-cut core biopsies before chemotherapy, and reverse-transcriptase-
mediated polymerase chain reaction (RT–PCR) after chemotherapy
Number of c494  MDR1 
Histology Size invaded nodes erb p53 Ki67 (%) ER PR MDR1 LRP Chemotherapy Response (RT–PCR)
Lobular 8.0 32 0 0 30 0 0 FAC4 SD 0
Ductal 7.0 31 1 1 60 0 0 Ttere-ADM4 PR 1
Ductal 6.0 21 1 1 30 1 1 1 FAC4 PR 1
Ductal 3.5 (T4b) 20 1 0 5 0 0 0 1 FAC3 PR 1
Ductal 6.0 20 0 0 35 0 0 1 1 FAC4 SD 1
Lobular 7.0 18 0 0 20 1 1 FAC4 PR 0
Ductal 3 (T4b) 16 0 0 30 1 1 0 1 FAC4 PR 1
Ductal Diffuse 15 0 0 20 0 0 FAC4 PR 0
Lobular Diffuse 11 0 0 80 1 1 1 1 FAC6 PR 1
Ductal 2.2 (T4b) 10 0 1 30 0 0 0 1 FAC4 PR 0
Ductal 7.0 10 0 0 35 1 0 1 1 FAC4 PR 1
Ductal 3 (T4b) 10 1 1 20 1 1 FAC4 PR Failed
Ductal 5.0 9 1 0 20 0 0 FAC4 SD Failed
Ductal 2.2+1.3 9 1 0 50 1 1 0 1 FAC4 PR 1
Ductal 4.0 (T4b) 8 1 1 1 1 FAC4 PR 0
Lobular 3.0 8 0 0 2 1 1 0 FAC4 SD 0
Ductal Diffuse 7 1 0 20 1 0 1 FAC4 SD 1
Ductal 8.0 7 1 1 50 0 0 1 1 FAC4 CCR 1
Ductal 5.0 (T4b) 5 0 0 5 0 0 FAC3 PR 0
Ductal Diffuse 4 0 0 50 1 0 1 FAC4 PR 1
Ductal 10.0 3 0 0 80 0 0 1 FAC3 PR Failed
Ductal 6.0 3 1 0 40 0 0 1 FAC4 SD 0
Ductal 4.5 (T4b) 2 0 0 30 1 1 FAC6 SD 1
Ductal 2.5 2 0 0 no 0 0 FAC4 PR Failed
Ductal 10.0 2 0 1 60 0 0 FAC4 CCR 1
Ductal 4.5+2.0 2 0 0 25 1 1 0 0 CMF4 PR 0
Ductal 5.0 2 1 1 40 1 0 0 FAC4 PR 0
Ductal 3.5 2 0 0 15 1 1 0 1 FAC4 SD 0
Ductal 3.0 2 0 1 35 0 0 1 FAC4 SD 0
Ductal 2.0 2 0 0 30 1 0 1 FAC4 PR 1
Ductal 2.6+2.3 1 0 0 40 1 1 FAC3 PR 1
Ductal 3.5 1 0 0 15 1 1 1 1 FAC4 PR 1
Undiff. 6.0 1 0 1 45 0 0 FAC6 SD 1
Lobular 6.0 1 0 0 10 1 1 0 0 FAC4 PR 0
Ductal 3.0 1 0 1 70 0 0 1 1 FAC2 PR 1
Ductal 5+2 0 1 1 20 0 1 FAC3 PR Failed
Ductal 3.5 0 1 0 12 0 0 0 0 FAC3 PR 0
Ductal 10.0 0 0 1 15 0 0 FAC5 SD 0
Ductal 6.0 0 0 1 15 1 1 FAC4 PR 1
Lobular 5.0 0 0 0 10 1 1 1 0 FAC4 PR 0
Ductal 5.0 0 0 0 10 1 1 FAC4 PR 0
Ductal 4.0 0 0 0 10 0 0 0 0 FAC4 PR 0
Ductal 5.0 0 0 0 10 1 1 0 1 FAC4 PR ND
Ductal 6.0 0 1 1 25 1 1 FAC4 PR 1
Ductal 2.0 (T4a) 0 1 1 30 1 1 FAC4 SD 0
Ductal 5.0 0 0 0 25 1 0 0 0 FAC4 PR 0
Ductal 5.0 0 0 0 15 1 1 0 0 FAC4 PR 0
Ductal 6.0 0 0 1 80 0 0 0 1 FAC4 PR 1
Ductal 3.6 0 0 0 10 1 1 1 1 FAC4 SD 0
Ductal 3.5 0 0 1 15 0 0 1 FAC4 PR 1
Ductal 4.0 0 0 0 20 1 0 1 FAC4 PR 0
Ductal 5.0 0 0 0 10 1 1 1 FAC4 PR 0
Responses: 1, positive, 0, negative. Positivity levels: MDR1 (c494), only membrane staining in more than 10% of tumor cells; LRP, more than 20%
reactive cells (for details, see the text). CCR, complete clinical response; PR, partial response; SD, stable disease; F, 5-fluorouracyl; A, doxorubicin
(adriamycin); C, cyclophosphamide; M, methotrexate; undiff, undifferentiated; ND, not done; Ttere, taxotere.diethyl pyrocarbonate-treated water). Then, 10% chelating
ion exchange resin (ChelexÒ 100; Bio-Rad) was added
before incubation of the mixture at 65ºC for 20 min. The
mixture was precipitated (8000 g, 10 min) and 100 ml of
the supernatant was used for total RNA extraction with
TrizolÒ (Gibco BRL) in accordance with the manufactur-
er’s instructions: a first lysis step in Trizol [40–60%
phenol, 10–20% guanidine thiocyanate, 5–10% ammo-
nium thiocyanate, water and glycerol), followed by a pre-
cipitation step at 14,000 g for 15 min. Afterwards, the
upper phase was transferred to a new tube, avoiding the
interphase, and precipitated in an equal volume of propan-
2-ol, then pelleted, washed and dried.
Total RNA, resuspended in diethyl pyrocarbonate-treated
water was treated with DNase. Two ml of 10×DNase
buffer (500 mM Tris–HCl, pH 8.0, 20 mM MgCl2) were
added, along with 1 ml of RNase-free bovine pancreatic
DNase I (40 U/ml; Boehringer Mannheim, Germany). This
mixture was incubated at room temperature for 30 min and
stopped by the addition of 0.1 vol. of 20 mM EDTA.
Efficient cDNA synthesis and MDR1 RT–PCR was
achieved by using a one-step method (SuperScript One
Step™ RT–PCR System; Gibco BRL). Total RNA, DNA-
free (3–10 ml), was added to a buffer containing each
dNTP at 0.2 mM as well as 1.2 mM MgSO4, 1 ml of Super-
Script™ II/RT/Taq mix (containing reverse transcriptase
and Taq DNA polymerase) and 0.2 mM of each specific
mdr1 primer (umdr1, 5¢-CCA TCA TTG CAA TAG CAG
G-3¢; dmdr1, 5¢-GAG CAT ACA TAT GTT CAA ACT TC-
3¢) and b-globin or GADPH (commonly used primers as
an internal amplification control). RT–PCR was performed
in a total volume of 25 ml. After incubation at 50°C for
20 min, the three-step PCR was performed for 35 cycles
in a Perkin–Elmer 9700 thermal cycler: 30 s denaturation
at 94°C, followed by annealing for 20 s at 52°C and finally
extension for 30 s at 72°C.
Loading buffer (1 ml) was added to a mixture containing
5 ml of both mdr1 and control amplified product and run in
a 3% (w/v) agarose gel at a constant 70 V in Tris–borate–
EDTA buffer for 45 min. The size of amplified bands was
168 base pairs (bp) for mdr1 and 130–400 for GADPH
and b-globin, depending on the primers used.
Because of the conserved nature of the GADPH and
b-globin genes, the coamplification of MDR1 with it results
in all cases in the presence of at least one visible band,
corresponding to the positive internal control, together
with a lower-weight control for mdr1 amplification (Fig. 1).
Statistics
For the analysis of the association of the different variables
with each other, we used Fisher’s exact test or Spear-
man’s correlation test for nonparametric variables, where
applicable. This was performed by means of the Graph-
Pad Prism statistical biomedical package (GraphPad Soft-
ware, San Diego, California, USA). Furthermore, the
strength of the association between each of the variables
and the presence or absence of invaded axillary nodes
(the endpoint of the study) was measured by means of
unconditional logistic regression after calculation of its
odds ratio, with the use of the STATA statistical package
(Stata, College Station, Texas, USA). As a first step, a uni-
variate analysis was performed (Table 2). Because MDR1
post-chemotherapy (RT–PCR) and LRP were interrelated
(all MDR1-positive cases were also LRP-positive), both
variables were subsequently combined into into a single
one with three different categories: both negative, MDR1-
negative/LRP-positive and both positive. Information about
this new variable was absent for 22 women. Given the rel-
atively small sample size of the study, these missing values
were treated as a separate category, which allowed us to
include them in the multivariate analysis.
All variables that proved to be predictive in the univariate
model were included in the multivariate analysis.
However, once again taking into account the small
sample number, we used less stringent significance crite-
ria than usual, including in the final model some variables
that failed to reach the common statistical boundary
defined by a P value of less than 0.05. Furthermore, we
tested whether or not the inclusion of any other predictor
Available online http://breast-cancer-research.com/content/3/3/183
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Figure 1
Ethidium-bromide-stained agarose gel after RT–PCR amplification of
MDR1 mRNA. The MDR1-expressing tumors are demonstrated by the
presence of a 168 base-pair band, above the b-globin positive control
(lanes 3, 4, 7, 8, 11, 13, 15, 16, 18, 20 and 22).improved the model. Finally, one powerful predictor for
nodal invasion emerging from the univariate analysis was
a histological variety different from ductal carcinoma (the
most common one). In fact, out of seven of the patients
carrying tumors with a different histology (six lobular and
one undifferentiated carcinoma), six presented axillary
invasion. To check the consistency of the odds ratios
obtained from the final model, this was therefore fitted
again, including only the homogeneous group of ductal
infiltrating carcinomas (Table 3).
Results
MDR1 expression was measured by means of RT–PCR in
rescue mastectomy specimens from patients previously
subjected to induction chemotherapy for locally advanced
breast cancer. MDR1-mRNA was successfully extracted
from 51/52 tumor paraffin blocks, and was effectively
retrotranscribed and amplified in 46/51 instances. Addi-
tionally, MDR1 expression before chemotherapeutic treat-
ment was assessed by means of immunohistochemistry in
23 cases. LRP expression before chemotherapy was
studied accordingly in 31 cases.
The pretherapeutic expression of LRP in more than 20%
of tumor cells was significantly correlated with the subse-
quent presence of axillary nodal metastases (Spearman’s
test, r = 0.4725, P = 0.0084). In the preliminary univariate
analysis giving rise to the final logistic regression model
employed, LRP-positivity almost attained statistical signifi-
cance for predicting nodal invasion (Table 2). Furthermore,
Breast Cancer Research    Vol 3 No 3 Schneider et al
Table 2
Univariate analysis of prognostic factors related to axillary lymph node invasion
Factor Variable No. of women Positive nodes (%) Odds ratio 95% CI P
Histology Ductal 45 29 (64%) 1.00
Other 7 6 (86%) 3.31 0.37–29.97 0.287
Tumor mass Single 36 21 (58%) 1.00
Other 16 14 (88%) 5.00 0.99–25.34 0.052
Clinical response No 13 (77%) 1.00
Yes 39 25 (64%) 0.54 0.13–2.28 0.398
ER Negative 22 16 (73%) 1.00
Positive 30 19 (63%) 0.65 0.20–2.14 0.477
PR Negative 28 21 (75%) 1.00
Positive 24 14 (58%) 0.47 0.14–1.52 0.205
c-erb-B2 Negative 37 24 (64%) 1.00
Positive 15 11 (73%) 1.49 0.37–5.62 0.557
53 Negative 34 24 (71%) 1.00
Positive 18 11 (61%) 0.65 0.20–2.18 0.489
Ki67 <20% 17 6 (35%) 1.00
³20% 33 27 (82%) 8.25 2.18–31.23 0.002
MDR1 (IHC) Negative 14 8 (57%) 1.00
Positive 9 7 (78%) 2.63 0.39–17.46 0.318
LRP Negative 8 3 (38%) 1.00
Positive 23 17  (74%) 4.72 0.86–26.04 0.075
MDR1 (RT–PCR) Negative 24 13 (54%) 1.00
Positive 22 18 (82%) 3.81 0.99–14.67 0.052
MDR1 (RT–PCR)  Both negative 8 3 (38%) 1.00
and LRP combined
LRP+ MDR1– 7 4 (57%) 2.22 0.28–17.63 0.450
Both positive 15 13 (87%) 10.83 1.37–85.43 0.024
CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; RT–PCR, reverse-transcriptase-mediated polymerase chain reaction.the immunohistochemical reaction is easy to judge
because the antibody can be employed at relatively low
concentrations for a monoclonal (see the Materials and
methods section), and thus gives virtually no background
staining (Fig. 2), which makes the detection of reactive
tumor cells very easy. No association of LRP expression
and the subsequent response to therapy could be dis-
cerned (although this observation is of little value, given
the low sample number and the fact that most tumors
showed some response).
MDR1 expression (membrane staining in more than 10%
of cells) measured by means of the c494 antibody (a
close relative of the c219 antibody widely used by us in
the past [14,15], but unfortunately one that works only on
freshly frozen material) was significantly correlated with
subsequent nodal invasion (Spearman’s test, r = 0.4763,
P = 0.022). However, significance was lost in the univari-
ate model (Table 2). The logistic regression model is much
more stringent, because it has to accommodate all data
and because missing data are included in it as a distinct
category, thus diluting the statistical power of some corre-
lations, which nevertheless do exist if analyzed individually
(as in this case).
The expression of MDR1 and that of LRP detected by
immunohistochemistry before chemotherapy were corre-
lated almost significantly (P = 0.12). Both were correlated
with MDR1 mRNA expression after chemotherapy (LRP,
r = 0.603, P = 0.0004; MDR1, r = 0.430, P = 0.052).
An extremely interesting finding was that, out of nine
immunohistochemically positive cases for MDR1 before
chemotherapy, seven were still positive on RT–PCR after
it. All seven of these patients had positive nodes. In con-
trast, the other two patients, who converted to MDR1-neg-
ative after treatment, had negative nodes. Despite the
extremely small number of patients involved, this yes/no
difference was statistically significant (Fisher’s exact test,
P = 0.028), and thus (with very much care) was not attrib-
utable to pure chance.
Finally, a Ki67 labeling index of at least 20% positive
tumor cells was also a significant predictor of axillary nodal
invasion. In contrast, the finding of a single, mobile tumor
mass confined to the breast gland, irrespective of size,
was associated almost significantly with the absence of
invaded nodes (Table 2).
Available online http://breast-cancer-research.com/content/3/3/183
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Figure 2
Strong reactivity with the LRP-56 monoclonal antibody of breast
cancer tumor cells, as opposed to the inert stromal background.
Streptavidin–biotin–peroxidase staining. Magnification ×400. 
Table 3
Multivariate analysis of prognostic factors related to axillary lymph node invasion
Including all tumours Including only ductal carcinomas
Factor Variable Odds ratio 95% CI P Odds ratio 95% CI P
Histology Ductal 1.00
Other 50.75 1.31–1968 0.035
Tumor mass Single 1.00 1.00
Other 4.64 0.66–32.60 0.123 4.62 0.66–32.21 0.122
Ki67 <20% 1.00 1.00
³20% 7.68 1.43–41.11 0.017 7.44 1.37–40.49 0.020
MDR1 and LRP Both negative 1.00 1.00
LRP+ MDR1– 9.16 0.36–232.1 0.179 8.45 0.32–223.6 0.202
Both positive 25.54 1.13–576.9 0.042 23.60 1.00–558.6 0.050
Unknown 4.78 0.29–79.26 0.275 4.38 0.25–78.42 0.315RNA of good enough quality for reverse transcription and
amplification was retrievable from the paraffin blocks corre-
sponding to 51/52 patients, and was successfully reverse-
transcribed and amplified in 46 of them (90.2%). Of these
46 patients, 22 showed the specific band corresponding
to the MDR1 mRNA (Fig. 1) and were therefore classified
as expressors of the gene. No attempts at further subclas-
sification of the expression level by band densitometry
were undertaken, although from Fig. 1 it is obvious that
there are indeed differences, even if an internal balance is
performed by comparison with the internal b-globin control.
MDR1 expression in the rescue mastectomies demon-
strated by this method was significantly correlated with
nodal invasion (Spearman’s test, r = 0.295,  P = 0.047)
when analyzed individually, and was associated with it
almost significantly in the univariate model (P = 0.052). In
fact, 18/22 positive cases (81.8%) showed nodal invasion,
against only 13/24 (54.2%) negative ones.
In the final, multivariate model accommodating all potential
predictors of axillary nodal invasion demonstrated by the
univariate analysis, the following independent prognostic
factors emerged: histology other than ductal, Ki67 at least
20%, and a combination of LRP-positivity before chemo-
therapy with MDR1 positivity after treatment. Tumor pre-
sentation different from a solitary mobile mass (namely,
diffuse T4a and T4b tumors in this study) attained almost
independent predictive value (Table 3).
Discussion
The role of resistance-associated genes in the develop-
ment of resistance to chemotherapy in humans is still con-
troversial. Breast cancer is no exception, and the MDR1
gene in particular has been extensively studied in connec-
tion with it, although no definitive conclusion has been
reached. Trock et al [16] addressed the possible signifi-
cance of the MDR1 gene in breast cancer through a large
meta-analysis, and cautiously stated in their conclusions
that ‘we found no evidence to support the assumption that
MDR1/gp170 expression has no role in breast cancer’
and, a little more daringly, that ‘while the precise role of
MDR1/gp170 in breast cancer remains to be established
definitively, it seems likely that, in tumors where expression
is detectable, this expression contributes to the multidrug-
resistant phenotype’. Our present findings seem only to
corroborate this statement.
Furthermore, throughout their paper Trock et al stressed
the difficulties imposed on their study by, for example, the
various methodologies employed in the different reports
that they considered, the heterogeneity of the patient pop-
ulations studied, and the different reactivity patterns of the
monoclonal antibodies used when performing immunohis-
tochemistry. We can only agree with all these points
raised, especially considering that 3 of the 31 studies
included in their meta-analysis were by our own group
[14,15,17], and we must humbly admit that their method-
ological criticisms largely apply to them (although also to
most, if not all, other studies considered). This, however,
speaks in favor of the plausible role of the MDR1 gene in
the development of resistance to chemotherapy in breast
cancer, which persisted throughout the meta-analysis, in
spite of the many justified criticisms of the studies
included in it.
In locally advanced breast cancer, where chemotherapy is
the mainstay of treatment, a possible implication of the
MDR1 gene in resistance and outcome has been found,
directly or indirectly, in most studies since the initial one by
Verrelle et al [18] until this present one. However, we have
previously also found consistently that MDR1 expression is
associated with the expression of the c-erb-B2 oncogene,
both in breast cancer and in ovarian cancer [15,17,19].
Support for the notion that there is indeed some relation-
ship between oncogenic activation including c-erb-B2
expression is provided by experimental evidence that the
transfection of c-erb-B2 and c-Ha-ras to human breast
epithelial cells that initially do not express the MDR1 gene
confers on them the full MDR phenotype. So, MDR1
expression could indirectly represent just an increased
malignancy of the tumors, and nodal invasion would simply
reflect their increased aggressiveness, and not the exis-
tence of chemotherapy-resistant tumor cell clones.
However, the multivariate analysis of the present study
shows that LRP and MDR1 expression is significantly
associated with nodal metastasis independently of a high
proliferation rate, which was another of the significant (and
independent) predictors identified here. In addition, MDR1
and c-erb-B2 were not significantly coexpressed this time,
which seems to contradict our previous reports; however,
this might be attributable to several causes, among which
are the different subsets of tumors studied in them (only
T4b tumors in one, which are a minority in this study, and
preselected, highly aggressive operable tumors in the
other), the use of different tumor material, at least in the
first study (frozen tumors), and the use of different anti-
bodies (c219 and NCL-pGlyP). In the present study, the
relationship of nodal invasion to the expression of MDR1
and LRP is therefore clearcut, and clearly outweighs an
eventual association with c-erb-B2 expression or high pro-
liferation. This might explain axillary node invasion purely
as a function of tumor aggressiveness via oncogenic acti-
vation, with MDR1 and LRP expression being only a by-
product of it.
Our findings seem to reflect the existence of intrinsically
resistant tumor cell clones before chemotherapeutic treat-
ment, and their persistence after it, from which metas-
tases, first local (nodal) and finally distant, might develop.
In favor of this hypothesis stands the fact that MDR1
expression after chemotherapy for locally advanced breast
Breast Cancer Research    Vol 3 No 3 Schneider et alcancer has been found to be associated with a worse final
outcome of the patients [11], and if breast cancer patients
die from their disease, they do so precisely because of
distant metatstases. From our results, finally, it seems
evident once more that resistance to chemotherapy is a
multifactorial phenomenon, where not just one but many
genes are involved.
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